Meeting
2015 ASCO Annual Meeting
SWOG 0709: A randomized phase II “pick-the-winner” trial of erlotinib (ERL) vs. ERL plus carboplatin/paclitaxel (C/T) in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) as selected by serum proteomics.
Authors
Primo Lara Jr.
UC Davis Comprehensive Cancer Center, Sacramento, CA
Primo Lara Jr., James Moon , Paul Joseph Hesketh , Mary Weber Redman , Stephen K. Williamson , Fred R. Hirsch , Philip C. Mack , David R. Gandara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00661193
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8040)
DOI
10.1200/jco.2015.33.15_suppl.8040
Abstract #
8040
Poster Bd #
362
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutation.
First Author: Youngjoo Lee
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2021 ASCO Annual Meeting
EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.
First Author: Christos Chouaid
Poster
2020 ASCO Virtual Scientific Program
Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size.
First Author: Sai-Hong Ignatius Ou